Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherState-of-the-Art (Invitation Only)

State-of-the-Art: FAPI PET/CT-Will it end the hegemony of FDG in oncology?

Rodney J. Hicks, Peter J Roselt, Kumarswamy G Kallur, Richard W. Tothill and Linda Mileshkin
Journal of Nuclear Medicine December 2020, jnumed.120.256271; DOI: https://doi.org/10.2967/jnumed.120.256271
Rodney J. Hicks
1 Peter MacCallum Cancer Institute, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rodney J. Hicks
Peter J Roselt
1 Peter MacCallum Cancer Institute, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumarswamy G Kallur
2 Healthcare Global Enterprises Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard W. Tothill
3 Department of Clinical Pathology and Centre for Cancer Research, University of Melbourne, Melbourne, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Mileshkin
4 Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

For over 40 years, FDG has been the dominant PET tracer in neurology, cardiology, inflammatory diseases and, most particularly, oncology. Combined with the ability to perform whole-body scanning, FDG has revolutionized the evaluation of cancer and has stifled the adoption of other tracers, except in situations where low avidity or high background activity limits diagnostic performance. The strength of FDG has generally been its ability to detect disease in the absence of structural abnormality, thereby enhancing diagnostic sensitivity, but its simultaneous weakness has been a lack of specificity due to divergent pathologies with enhanced glycolysis. Radiotracers that leverage other hallmarks of cancer or specific cell-surface targets are gradually finding a niche in the diagnostic armamentarium. However, none have had sufficient sensitivity to realistically compete with FDG for evaluation of the broad spectrum of malignancies. Perhaps, this situation is about to change with development of a class of tracers targeting fibroblast activation protein (FAP) that have low uptake in almost all normal tissues but high uptake in diverse cancer types. In this review, the development and exciting preliminary clinical data relating to various FAP-specific small-molecule inhibitor (FAPI) tracers in oncology, will be discussed along with potential non-oncological applications.

  • Molecular Imaging
  • PET/CT
  • Radiochemistry
  • PET
  • fibroblast activation protein
  • oncology
  • radiochemistry
  • theranostics
  • Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (5)
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
State-of-the-Art: FAPI PET/CT-Will it end the hegemony of FDG in oncology?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
State-of-the-Art: FAPI PET/CT-Will it end the hegemony of FDG in oncology?
Rodney J. Hicks, Peter J Roselt, Kumarswamy G Kallur, Richard W. Tothill, Linda Mileshkin
Journal of Nuclear Medicine Dec 2020, jnumed.120.256271; DOI: 10.2967/jnumed.120.256271

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
State-of-the-Art: FAPI PET/CT-Will it end the hegemony of FDG in oncology?
Rodney J. Hicks, Peter J Roselt, Kumarswamy G Kallur, Richard W. Tothill, Linda Mileshkin
Journal of Nuclear Medicine Dec 2020, jnumed.120.256271; DOI: 10.2967/jnumed.120.256271
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

State-of-the-Art (Invitation Only)

  • Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE guidelines)
  • Single cell radiotracer allocation via immunomagentic sorting (scRadiotracing) to disentangle PET signals at cellular resolution
  • The Importance of Training, Accreditation and Guidelines for The Practice of Theranostics: The Australian Perspective
Show more State-of-the-Art (Invitation Only)

Clinical (Oncology: Other)

  • CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
  • Dual-tracer PET/CT protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for cancer imaging - a proof of concept.
  • The Importance of Training, Accreditation and Guidelines for The Practice of Theranostics: The Australian Perspective
Show more Clinical (Oncology: Other)

Similar Articles

Keywords

  • molecular imaging
  • PET/CT
  • Radiochemistry
  • PET
  • Fibroblast Activation Protein
  • oncology
  • Theranostics
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire